UNSPSC 51132215: Acetaminophen/caffeine/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132215 Acetaminophen/caffeine/salicylamide is a Commodity code that in practice covers a narrower scope than the code name suggests — state and local buyers are using it to solicit pharmaceuticals and over-the-counter health products more broadly, including naloxone, generic multi-source pharmaceuticals, and OTC items supplied through authorized wholesale channels. The issuing bodies span state health and human services agencies, county health departments, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Work under the code includes direct vendor procurement of pharmaceutical products with specific regulatory compliance (cGMP, Drug Supply Chain Security Act certification, FDA requirements), inventory management tied to quarterly or ongoing deliveries, and fulfillment through established wholesaler networks or direct-to-manufacturer relationships.

Recent activity shows geographically dispersed solicitation across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, response due July 26, 2023 (note: due date appears to be a data entry error in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling future formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026; awarded vendors must maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. and demonstrate pricing flexibility across multiple formats (flat price, net price, WAC-minus structures).